Ametefgene parvec

哌阿替夫基

Report date: 2026/05/07 20:00:36

Base Information

Drug NameAmetefgene parvec
Drug Alias NameAMT-140AB-1005AAV2-GDNFAAV2-GDNF-MSAAAV2-GDNF-PD
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionNeurons stimulantsGene transferenceGlial cell line-derived neurotrophic factors stimulants
TargetsGlial cell line-derived neurotrophic factors
Therapy Area/IndicationsParkinson DiseaseMultiple System Atrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandGermany +[5] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesUc San Francisco
China Registration ClassN/A

Develop Information

Active CompaniesAskBio IncBayer AG
Inactive CompaniesN/A
Active IndicationsParkinson DiseaseMultiple System Atrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A